Melt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain and Sedation Drug Candidate
February 09, 2021 07:00 ET
|
Melt Pharmaceuticals; Harrow Health, Inc.
BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first-in-class medicines for sedation and analgesia, announced results from...
Melt Pharmaceuticals Enters the Clinical Stage of MELT-100 Development
July 29, 2020 07:00 ET
|
Melt Pharmaceuticals
FDA has accepted MELT-100 IND; Phase 1 study enrollment to start immediately BOSTON, July 29, 2020 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing...
Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulations
February 13, 2019 07:00 ET
|
Harrow Health, Inc.; Melt Pharmaceuticals
SAN DIEGO and BOSTON, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, Inc., a specialty pharmaceutical company recently deconsolidated from Harrow Health, Inc. (NASDAQ: HROW), today...
Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiary
February 05, 2019 07:00 ET
|
Harrow Health, Inc.; Melt Pharmaceuticals, Inc.
SAN DIEGO and BOSTON, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, Inc., an affiliated company of Harrow Health, Inc. (NASDAQ: HROW), today announced it has entered into definitive stock...